Multiple Sclerosis Therapeutics Market Segments, Top Key Players, Drivers And Trends 2022

According to Precision Business Insights (PBI), the latest report, the market value of the multiple sclerosis therapeutics market size is expected to be valued at USD 27,534.2 million in 2022 and is expected to grow at a CAGR of 5.6% in 2022-2028. The primary factors that drive the market are the growing focus on research and development to innovate novel drugs by chief market players, new launches of products, growing government initiatives to expand the availability of care and treatment, and the increasing prevalence of multiple sclerosis.

View the detailed report description here - https://precisionbusinessinsights.com/market-reports/multiple-sclerosis-therapeutics-market/

Oral to Dominate the Multiple Sclerosis Therapeutics Market:
Based on the route of administration type, oral holds the highest market share. The major factor for the rise of this segment is that it encourages patient satisfaction and surges therapeutic acquiescence. Important therapeutic developments in the new orally administered therapeutics permitted for multiple sclerosis treatment can drive the global multiple sclerosis therapeutics market growth. Three oral drugs that have been permitted by regulatory bodies to cure multiple sclerosis are fingolimod, dimethyl fumarate, and teriflunomide.

North America Multiple Sclerosis Therapeutics Market:
North America leads the global multiple sclerosis therapeutics market growth due to the surge in demand for multiple sclerosis therapeutic products. North America leads the global market due to entrenched research infrastructure, increasing funding from public and private sectors, and rising collaborations among global key players have contributed to increasing the sales of multiple sclerosis therapeutics in this region. Apart from this, the major factor that drives the market is the increasing prevalence of multiple sclerosis. As per the Global Burden of Disease Study, 2016, North America reported the highest age-standardized multiple sclerosis prevalence at 164.6 per 100,000 population.

Strategic New Product Launches, Mergers, Acquisitions, and Agreements are the key strategies adopted by market players:
The global multiple sclerosis therapeutics market further reveals that the key players are implementing strategies such as the extension of product collection through research and development activities, product launches, acquisitions, mergers, and strategic alliances to improve their market position and strengthen the market revenue share. In December 2020, Adamas Pharmaceuticals Inc. announced the results of ADS5102 in its phase III trial which is a multiple sclerosis treatment drug. In April 2021, Biogen announced that the European Commission (EC) 20 arranged to the marketing support for subcutaneous injection of TYSABRI (natalizumab) to treat relapsing-remitting multiple sclerosis

Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=61900

The multiple sclerosis therapeutics markets is segmented based on, product type, route of administration, and region.
Based on the product type, the market is segmented into the following:
• Immunosuppressants
• Immunomodulators

Based on the route of administration type, the market is segmented into the following:
• Oral
• Injectable
• Intravenous

Based on the region, the market is segmented into the following:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Request Methodology: https://precisionbusinessinsights.com/request-methodology?product_id=61900

Key players' profiles in the multiple sclerosis therapeutics market report are Biogen (U.S.), Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Sanofi (France), Teva Pharmaceutical Industries Ltd. (Israel), Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation) (New Jersey), and Bristol-Myers Squibb Company (U.S.)

Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 85278174

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.